Uterine sarcoma: a report of 57 cases over a 16-year period analysis

Uterine sarcomas comprese approximately 4-9% of all uterine malignant tumors with a poor prognosis. We report 57 cases of sarcoma originating in the uterus treated from 1990 to 2006 at the Department of Obstetrics and Gynecology of Democritus University of Thrace, Greece and the Department of Obstetrics and Gynecology of Aschaffenburg Hospital, Germany. The median age of occurrence was 49 years with the commonest symptom being abnormal uterine bleeding. Forty-nine patients underwent a total hysterectomy and bilateral salpingo-oophorectomy whereas 17 cases underwent radical lymph adenectomy. During the last follow-up (December 2006), six patients were alive and well with no evidence of disease, 23 patients had died of undercurrent disease, and 28 were alive with recurrence of disease. These rare cancers can be aggressive, and account for a greatly disproportionate number of deaths from uterine cancers. Treatment for this rare disease should be performed according to international protocols in order to have the most updated information.

Uterine sarcoma; Surgical; Postoperative treatment; Follow-up

[1] Trimble E.L., Harlan L.C., Clegg L.X., J.L. Stevens: “Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States”. Gynecol. Oncol., 2005, 96, 741.

[2] Brooks S.E., Zhan M., Cote T., C.R.Baquet: “Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999”. Gynecol. Oncol., 2004, 93, 204

[3] Livi L., Paiar F., Shah N., Blake P., Villanucci A., Amunni G. et al.: “Uterine sarcoma: twenty-seven years of experience”. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57, 1366.

[4] Knocke T.H., Kucera H., Dörfler Daniela, Pokrajac B., R. Pötter: “Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri”. Cancer, 1998, 83, 1972.

[5] Salazar O.M., Bonfiglio T.A., Patten S.F., Keller B.E., Feldstein M., Dunne M.E. et al.: “Uterine sarcomas: natural history, treatment and prognosis”. Cancer, 1978, 42, 1152.

[6] Echt G., Jepson J., Langholz B., Luxton G., Hernandez W. et al.: “Treatment of uterine sarcomas”. Cancer, 1990, 66, 35,

[7] Dinh T.A., Oliva E.A., Fuller A.F., Lee H., A.Goodmann: “The treatment of uterine leiomyosarcoma. Results from a 10-year experience (190-1999) at the Massachusetts General Hospital”. Gynecol. Oncol., 2004, 92, 648.

[8] DiSaia P.J., Creasman W.T.: “Sarcoma of the uterus”. Clinical Gynecologic Oncology, St. Louis, Mosby, 1993, 156.

[9] Leath C.A., 3rd, Huh W.K., Hyde J. Jr., Cohn D.E., Resnick K.E., Taylor N.P. et al.: “A multi-institutional review of outcomes of endometrial stromal sarcoma”. Gynecol. Oncol., 2007, 22.

[10] Friedrich M., Villena-Heinsen C., Mink D., Bonkhoff H., Schmidt W.: “Carcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol., 1999, 82, 85.

[11] Fischer B., Costantino J., Redmond C. K., Fisher E.R, Wickerham L., Cronin W.M.: “Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Projeect (NSABP), B14 [prior annotation incorrect] [ see comment citations in Medline]. J. Nat. Cancer. Inst., 1994, 86, 527.

[12] Rovirosa A., Ascaso C., Ordi J., Abellana R., Arenas M., Lejarcegui J.A. et. al.: “Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages”. Int. J. Radiat. Oncol. Biol. Phys., 2002, 52, 1320.

[13] Buttram V.C., Reiter R.C.: “Uterine leiomyomata-etiology, symptomatology and management”. Fertil. Steril., 1981, 36, 433.

[14] Benagiano G., Morini A., Primiero F.M.: “Fibroids: overview of current and future treatment options”. Br. J. Obstet. Gynecol., 1992, 99, 18.

[15] Livi L., Paiar F., Shah N., Blake P., Villanucci A., Amunni G.: “Uterine sarcoma: twenty-seven years of experience”. Int. Radiat. Oncol. Biol. Phys., 2003, 57, 1366.

[16] Berkowitz R.S., Goldstein D.P.: “Uterine cancer”. In Berek J.S., Hacker N.E. (eds.). Practical Gynecologic Oncology, 4th edition. Lippincott, Williams & Wilkins, England, 2005, 431.

[17] Parker W.H., Fu W.S., Berek J.S.: “Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma”. Obstet. Gynecol., 1984, 83, 414.

[18] Bodner K., Bodner-Adler B., Obermair A., Windbichler G., Petru E., Mayerhofer S. et al.: “Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients”. Gynecol. Oncol., 2001, 81, 160.

[19] Nordal R.R., Kristensen G.B., Kaern J., Stenwig A.E., Pettersen E.O., Trope C.G: “The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma”. Gynecol. Oncol., 1996, 62, 254.

[20] Haberal A., Kayikcioglu F., Boran N., Caliskan E., Özgül N., M.F. Köse: “Endometrial stromal sarcoma of the uterus: analysis of 26 patients”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2003, 209.

[21] Schwartz S.M., Thomas D.B.: “A case-control study of risk factors for sarcomas of the uterus. The world Health Organization collaborative study of neoplasia and steroid contraceptives”. Cancer, 1989, 64, 2487.

[22] Demeestere I., Simon P., Buxant F., Robin V., Fernandez S.A., Centner J. et al.: “Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report”. Human. Reprod., 2006, 21, 2010.

[23] WallaceW.H., Anderson R.A., Irvine D.S.: “Fertility preservation for young patients with cancer: who is at risk and what can be offered?”. Lancet Oncol., 2005, 6, 209.

[24] Berchuck A., Rubin S.C., Hoskins W.J., Saigo P.E., Pierce V.K., Lewis J.L., Jr.: “Treatment of uterine leiomyosarcoma” (review). Obstet. Gynecol., 1988, 71 (6 Pt 1), 845.

[25] Ashraf-Ganjoei T., Behtash N., Shariat M., Mosavi A.: “Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases”. World J. Surg. Oncol., 2006, 4, 50.

[26] Olah K.S., Gee H., Blunt S., Dunn J.A., Kelly K., Chan K.K.: “Retrospective analysis of 318 cases of uterine sarcoma”. Eur. J. Cancer, 1991, 27, 1095.

[27] Tinkler S.D., Cowie V.J.: “Uterine sarcomas: a review of the Edinburgh experience from 1974 to 1992”. Br. J. Radiol., 1993, 66, 998.

[28] Wolfson A.H., Wolfson D.J., Sittler S.Y., Breton L., Markoe A.M., Schwade J.G., et al.: “A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas”. Gynecol. Oncol., 1994, 52, 56.

[29] Yamada S.D., Burger R.A., Brewster W.R., Anton D., Kohler M.F., Monk B.J.: “Pathologic variables and adjuvant therapy as predictors of recurrences and survival for patients with surgically evaluated carcinosarcoma of the uterus”. Cancer, 2000, 88, 2782.

[30] Smith H.O., Blessing J.A., Vaccarello L.: “Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group”. Gynecol. Oncol., 2002, 84, 140.

[31] Gallup D.G., Blessing J.A., Andersen W., Morgan M.A.: “Gynecologic Oncology Group study evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus:a gynaecologic oncology group study”. Gynecol. Oncol., 2003, 89, 48.

[32] Sutton G., Blessing J.A., Ball H.: “Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1999, 74, 346.

[33] Livi L., Andreopoulou E., Shah N., Paiar F., Blake P., Judson I., Harmer C.: “Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998”. Clin. Oncol. (R. Coll. Radiol.), 2004, 16, 261.

[34] Tore G., Topuz E., Bilce N., Aslay I., Dincer M., Elgin A.: “The role of adjuvant chemotherapy in the treatment of uterine sarcoma patients”. Eur. J. Gynaecol. Oncol., 1990, 11, 307.

[35] Kelly K.L., Craighead P.S.: “Characteristics and management of uterine sarcoma patients treated at the Tom Baker Cancer Centre”. Int. J. Gynecol. Cancer, 2005, 15, 132.

[36] Nordal R.R., Thoresen S.O.: “Uterine sarcomas in Norway 1956- 1992: incidence, survival and mortality”. Eur. J. Cancer, 1997, 33, 907.

[37] Wheelock J.B., Krebs H.B., Schneider V., Goplerud D.R.: “Ute ri - ne sarcoma: analysis of prognostic variables in 71 cases”. Am. J. Obstet. Gynecol., 1985, 151, 1016.

[38] Nordal R.R., Kristensen G.B., Stenwig A.E., Nesland J.M., Pettersen E.O., Trope C.G.: “An evaluation of prognostic factors in uterine carcinosarcoma”. Gynecol. Oncol., 1997, 67, 316.

[39] Wolfson A.H., Wolfson D.J., Sittler S.Y., Breton L., Markoe A.M., Schwade J.G. et al.: “A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas”. Gynecol. Oncol., 1994, 52, 56.

[40] Larson B., Silfversward C., Nilsson B., Pettersson F.: “Endometrial stromal sarcoma of the uterus. A clinical and histopathological study. The Radiumhemmet series 1936-1981. Eur. J. Obstet. Gynecol. Reprod. Biol., 1990, 35, 239.

[41] Vaccarello L., Curtin J.P.: “Presentation and management of carcinosarcoma of the uterus”. Oncology (Williston Park). 1992, 6, 45.

[42] Piver M.S., Lele S.B., Marchetti D.L., Emrich L.J.: “Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas”. J. Surg. Oncol., 1988, 38, 233.

[43] Gadducci A., Fabrini M.G., Facchini V., Ducci F., Colosimo S., Dell’Arciprete T. et al.: “Surgery and radiotherapy in the treatment of early stage uterine sarcomas”. Eur. J. Gynaecol. Oncol., 1989, 10, 276.

[44] Goff B.A., Rice L.W., Fleischhacker D., Muntz H.G., Falkenberry S.S., Nikrui N., Fuller A.F., Jr.: “Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence”. Gynecol. Oncol., 1993, 50, 105.

[45] Duk J.M., Bouma J., Burger G.T., Nap M., De Bruijn H.W.: “CA125 in serum and tumor from patients with uterine sarcoma”. Int. J. Gynecol. Cancer, 1994, 4, 156.